Population pharmacokinetics of the rilpivirine long-acting formulation after intramuscular dosing in healthy subjects and people living with HIV
出版年份 2021 全文链接
标题
Population pharmacokinetics of the rilpivirine long-acting formulation after intramuscular dosing in healthy subjects and people living with HIV
作者
关键词
-
出版物
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Volume -, Issue -, Pages -
出版商
Oxford University Press (OUP)
发表日期
2021-09-08
DOI
10.1093/jac/dkab338
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection
- (2020) Chloe Orkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression
- (2020) Susan Swindells et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults
- (2019) Scott L Letendre et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Long-acting injectable therapy
- (2019) Ronald D’Amico et al. Current Opinion in HIV and AIDS
- Population pharmacokinetics of Rilpivirine in HIV-1-infected patients treated with the single-tablet regimen rilpivirine/tenofovir/emtricitabine
- (2018) Nadège Néant et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial
- (2017) David A Margolis et al. LANCET
- Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals
- (2016) Manel Aouri et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Safety, tolerability and pharmacokinetics of rilpivirine following administration of a long-acting formulation in healthy volunteers
- (2015) R Verloes et al. HIV MEDICINE
- Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial
- (2015) David A Margolis et al. LANCET INFECTIOUS DISEASES
- Formulation and pharmacology of long-acting rilpivirine
- (2015) Peter E. Williams et al. Current Opinion in HIV and AIDS
- Long-acting antiviral agents for HIV treatment
- (2015) David A. Margolis et al. Current Opinion in HIV and AIDS
- A Compartmental Pharmacokinetic Evaluation of Long-Acting Rilpivirine in HIV-Negative Volunteers for Pre-Exposure Prophylaxis
- (2014) A G A Jackson et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Pharmacokinetics, Safety, and Tolerability With Repeat Doses of GSK1265744 and Rilpivirine (TMC278) Long-Acting Nanosuspensions in Healthy Adults
- (2014) William Spreen et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Lack of Pharmacokinetic Interaction between Rilpivirine and Integrase Inhibitors Dolutegravir and GSK1265744
- (2013) Susan L. Ford et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Impact of Food and Different Meal Types on the Pharmacokinetics of Rilpivirine
- (2013) Herta M. Crauwels et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Improving the Success Rate of Gluteal Intramuscular Injections
- (2013) April E. Boyd et al. PANCREAS
- Beyond virological suppression: the role of adherence in the late HAART era
- (2012) Adriana Ammassari et al. ANTIVIRAL THERAPY
- Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models
- (2011) Martin Bergstrand et al. AAPS Journal
- Effect of intrinsic and extrinsic factors on the pharmacokinetics of TMC278 in antiretroviral-naïve, HIV-1-infected patients in ECHO and THRIVE
- (2010) HM Crauwels et al. Journal of the International AIDS Society
- TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1
- (2009) H. Azijn et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment
- (2009) Lieven Baert et al. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started